Biologics and Novel Therapeutics Library
ISO 17025–ACCREDITED LABORATORY ENVIRONMENT
Monoclonal Antibodies DMPK and Bioanalytical Services
Monoclonal antibody bioanalysis requires a biologics-specific DMPK framework. mAbs such as nivolumab are interpreted through in vivo exposure, capture strategy, proteolytic catabolism, intact antibody signal, surrogate peptide readout, and Fab / Fc region integrity rather than CYP metabolism or transporter routing.
Creative Proteomics develops research-use mAb bioanalytical workflows that combine in vivo sample analysis, ligand-binding assay support, immunoaffinity enrichment, LC-MS surrogate peptide quantification, intact and subunit antibody characterization, protease-linked degradation review, and Fab / Fc analysis.
Biologics ExposureMeasure mAb signal in in vivo matrices using platform-specific capture and quantification strategies.
Fab / Fc ResolutionSeparate intact, subunit, region-specific, and surrogate peptide readouts when interpretation requires it.
Proteolytic FateReview mAb catabolism, degradation products, and digestion-related artifacts without forcing a small-molecule MetID model.
Monoclonal Antibody Study Logic CAPTURE → REGION → CATABOLISM
🧲
Capture StrategyLigand-binding, immunoaffinity, or hybrid workflows are selected by matrix and specificity needs.
🧬
Surrogate Peptide ReadoutLC-MS peptide targets can quantify exposure when digestion and peptide selection are controlled.
🔬
Fab / Fc IntegrityRegion-aware analysis supports intact, reduced, subunit, or peptide-level interpretation.
🧫
Protease-Linked CatabolismmAb degradation and fragment patterns are interpreted as biologics catabolic fate, not CYP Phase I metabolism.
Biologics-specific mAb bioanalysis.We connect in vivo sample bioanalysis, capture strategy, LC-MS surrogate peptide quantification, intact/subunit analysis, Fab / Fc interpretation, and protease-linked degradation review.
